Brian Lian, Ph.D., is the CEO of Viking Therapeutics, Inc., a position he has held since June 2, 2014. His leadership has been key as the company focuses on developing therapies for metabolic and endocrine disorders. Over the years, Dr....

Brian Lian, Ph.D., is the CEO of Viking Therapeutics, Inc., a position he has held since June 2, 2014. His leadership has been key as the company focuses on developing therapies for metabolic and endocrine disorders. Over the years, Dr. Lian's compensation has reflected the company's growth, with his total pay reaching nearly $1 million in 2023. This includes a salary of $615,000 and a bonus reflecting his performance and corporate objectives. Notably, his stock options and performance-linked equity grants, totaling over $4 million in value, show his vested interest in the company's success. Dr. Lian has made significant insider trades over the years, with the value of his holdings peaking at $84.52 million in February 2024, indicating a strong financial stake in the company's future. His approach to executive compensation aligns with performance metrics, aimed at motivating the team towards achieving key milestones, which is crucial in the competitive biotech industry. His focus remains on driving Viking Therapeutics forward, marking a path towards innovative treatment options that can impact many lives.